On August 17, LEADS BIOLABS-B rose 5.18% in regular trading, trading at HK$76.95/share, with turnover of HK$64.37 million.

The rise extends recent momentum fueled by a series of clinical milestones. Most recently, the company's core product Weilisin (Opamtistomig, a PD-L1/4-1BB bispecific antibody) saw its Phase II study for first-line hepatocellular carcinoma successfully enter the expansion stage following positive efficacy signals. Additionally, the IND application for Weilisin in metastatic colorectal cancer was approved by China's CDE, while the biliary tract cancer Phase II study completed enrollment of all 70 patients.

Further supporting sentiment, Weilisin's biologics license application for extrapulmonary neuroendocrine carcinoma was included in the priority review program, and six research results were selected for the ESMO annual meeting, including two highest-tier oral presentations. Zheshang Securities initiated coverage with a Buy rating, projecting revenue growth of 60%, 39%, and 91% for the next three years respectively.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)